ong-term safety of trastuzumab in patients with HER2-positive breast cancer
Completed
- Conditions
- decrease of left ventricular ejection fraction1001928010027656
- Registration Number
- NL-OMON33506
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+ using the HercepTestTM, or gene amplification by fluorescence in situ hybridization, or chromogenic in situ hybridization (CISH)
Exclusion Criteria
Pregnancy or breast feeding
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- Left ventricular ejection fraction (LVEF)</p><br>
- Secondary Outcome Measures
Name Time Method <p>- NT-proBNP en troponin T analysis<br /><br>- New York Heart Association (NYHA)<br /><br>- genotype analysis<br /><br>- electrocardiogram</p><br>